Side effects in cancer treatment and allergological safety: Early diagnosis of severe cutaneous adverse reactions caused by anticancer drugs and development of joint care algorithms by an allergist

Background: Modern cancer therapies, alongside their efficacy, frequently cause adverse effects on the skin and mucous membranes [1,2].Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and DRESS syndrome, are life-threatening [2, 15].Objective: To early diagnose severe cutaneous adverse reactions induced by anticancer drugs, differentiate them from common inflammatory conditions, and develop multidisciplinary joint care algorithms involving oncologists and allergists.Methods: Systematic reviews and clinical case series published between 2013 and 2026 in PubMed, Embase, Web of Science, and Scopus databases were analyzed in accordance with PRISMA guidelines [7, 9].HLA alleles (e.g., HLA-B*15:02), TCR repertoires, and rapid desensitization (RDD) protocols were reviewed [6, 9].Results: Skin reactions range from mild xerosis to severe conditions such as SJS/TEN [7].TCR, HLA, and metabolic SNPs were found to play a significant role in SCAR pathogenesis [6, 15].RDD protocols for taxanes demonstrated 95-100% efficacy, allowing treatment continuation without interruption [9]. Conclusion:The integration of oncology and allergology (onco-allergology) requires multidisciplinary algorithms to prevent the unjustified discontinuation of vital cancer therapy and enhance patient safety.